{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:03:13Z","timestamp":1789646593426,"version":"4.0.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1097\/md.0000000000006022","type":"journal-article","created":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T21:05:45Z","timestamp":1495573545000},"page":"e6022","source":"Crossref","is-referenced-by-count":13,"title":["Impact of patient and treatment characteristics on glycemic control and hypoglycemia in patients with type 2 diabetes initiated to insulin glargine or NPH"],"prefix":"10.1097","volume":"96","author":[{"given":"Francesca","family":"Porcellati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Lucidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geremia B.","family":"Bolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine G.","family":"Fanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-59-20210226","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"R3-59-20210226","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"Gerstein","year":"2012","journal-title":"N Engl J Med"},{"key":"R4-59-20210226","doi-asserted-by":"crossref","first-page":"S220","DOI":"10.2337\/dc11-s224","article-title":"Pivotal role of timely basal insulin replacement after metformin failure in sustaining long-term blood glucose control at a target in type 2 diabetes","volume":"34","author":"Bolli","year":"2011","journal-title":"Diabetes Care"},{"key":"R5-59-20210226","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.2337\/dc10-1911","article-title":"Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study","volume":"34","author":"Lucidi","year":"2011","journal-title":"Diabetes Care"},{"key":"R6-59-20210226","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.2337\/diabetes.49.12.2142","article-title":"Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro","volume":"49","author":"Lepore","year":"2000","journal-title":"Diabetes"},{"key":"R7-59-20210226","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.numecd.2014.02.008","article-title":"Glargine metabolism over 24\u200ah following its subcutaneous injection in patients with type 2 diabetes mellitus: a dose-response study","volume":"24","author":"Lucidi","year":"2014","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"R8-59-20210226","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1463-1326.2011.01543.x","article-title":"Metabolic control and risk of hypoglycaemia during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis","volume":"14","author":"Pontiroli","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"R9-59-20210226","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.diabres.2006.08.012","article-title":"Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients","volume":"76","author":"Pan","year":"2007","journal-title":"Diabetes Res Clin Pract"},{"key":"R10-59-20210226","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.arcmed.2005.10.015","article-title":"Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride","volume":"37","author":"Eliaschewitz","year":"2006","journal-title":"Arch Med Res"},{"key":"R11-59-20210226","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s00125-005-0132-0","article-title":"Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study","volume":"49","author":"Yki-Jarvinen","year":"2006","journal-title":"Diabetologia"},{"key":"R12-59-20210226","doi-asserted-by":"crossref","first-page":"952","DOI":"10.7326\/0003-4819-138-12-200306170-00006","article-title":"Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial","volume":"138","author":"Fritsche","year":"2003","journal-title":"Ann Intern Med"},{"key":"R13-59-20210226","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","article-title":"The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients","volume":"26","author":"Riddle","year":"2003","journal-title":"Diabetes Care"},{"key":"R14-59-20210226","first-page":"445","article-title":"Efficacy and safety of insulin glargine in concurrent use with oral hypoglycemic agents for the treatment of type 2 diabetes patients","volume":"19","author":"Kawamori","year":"2003","journal-title":"Rinsho Iyaku"},{"key":"R15-59-20210226","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1507\/endocrj.EJ11-0206","article-title":"Effect of obesity on declining beta cell function after diagnosis of type 2 diabetes: a possible link suggested by cross-sectional analysis","volume":"59","author":"Saisho","year":"2012","journal-title":"Endocr J"},{"key":"R16-59-20210226","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.2337\/dc11-1064","article-title":"Differential effects of adiposity on pharmacodynamics of basal insulins NPH, glargine, and detemir in type 2 diabetes mellitus","volume":"34","author":"Porcellati","year":"2011","journal-title":"Diabetes Care"},{"key":"R17-59-20210226","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1007\/s00125-009-1534-1","article-title":"Increased insulin dose requirement of long-acting insulin analogues in obese patients with type 2 diabetes","volume":"52","author":"Schmid","year":"2009","journal-title":"Diabetologia"},{"key":"R18-59-20210226","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.diabres.2014.08.003","article-title":"Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: a pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials","volume":"106","author":"Owens","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"R19-59-20210226","doi-asserted-by":"crossref","first-page":"23","DOI":"10.17925\/EE.2014.10.01.23","article-title":"A patient-level analysis of efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine added to oral antidiabetes agents in people with type 2 diabetes","volume":"10","author":"DeVries","year":"2014","journal-title":"Eur Endocrinol"},{"key":"R20-59-20210226","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1172\/JCI113338","article-title":"Quantitative study of insulin secretion and clearance in normal and obese subjects","volume":"81","author":"Polonsky","year":"1988","journal-title":"J Clin Invest"},{"key":"R21-59-20210226","doi-asserted-by":"crossref","first-page":"b5444","DOI":"10.1136\/bmj.b5444","article-title":"The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study","volume":"340","author":"Miller","year":"2010","journal-title":"BMJ"},{"key":"R22-59-20210226","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/fampra\/cms071","article-title":"A retrospective study on the incidence and risk factors of severe hypoglycemia in primary care","volume":"30","author":"Samann","year":"2013","journal-title":"Fam Pract"},{"key":"R23-59-20210226","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2337\/dc14-1329","article-title":"Predictors of nonsevere and severe hypoglycemia during glucose-lowering treatment with insulin glargine or standard drugs in the ORIGIN trial.","volume":"38","year":"2015","journal-title":"Diabetes Care"},{"key":"R24-59-20210226","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2337\/dc14-0649","article-title":"Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes","volume":"38","author":"Porcellati","year":"2015","journal-title":"Diabetes Care"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000006022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:42:57Z","timestamp":1620960177000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201702030-00059"}},"subtitle":["A post hoc, pooled, patient-level analysis of 6 randomized controlled trials"],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000006022","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]}}}